|
|
cas 31098-42-7 |
CLASS VARIOUS RADIATION-PROTECTIVE AGENTS REDUCTION OF THE CUMULATIVE RENAL TOXICITY OF CISPLATIN AND FOR THE REDUCTION OF THE TOXIC EFFECTS OF RADIATION ON NORMAL ORAL TISSUES SCAVENGE REACTIVE OXYGEN SPECIES |
|
ATC code
V03AF05 |
PK parameters Cmax 35 MICROMOLAR t1/2 0.13 HOUR
|
TargetTARGET ALKALINE PHOSPHATASE PDB 7NIZ (HUMAN 14-3-3 SIGMA IN COMPLEX WITH HUMAN ESTROGEN RECEPTOR ALPHA PEPTIDE AND LIGANDS FUSICOCCIN-A AND WR-1065) Ligand code = UGH (link to the list of PDB complexes) Download experimental 3D coordinates of UGH with added hydrogens |
DrugCentral Unknown |
Download SDF file |
Ethanethiol, 2-[(3-aminopropyl)amino]- Formula: C5H14N2S Calculated chemical properties: MW 134.25 NB_atoms 8 XLogP -0.15 PSA 39.888 NB_HD 3 NB_HA 2 fsp3 1.00 Lipinski(0=no;1=yes) 1 |
|
Other links: PubChem ChemicalProbes U.S. repository of Clinical Trials VigiAccess SIDER side effects ChemSynthesis Patent@SureChEMBL |
|
|
cas 20537-88-6 |
CLASS VARIOUS RADIATION-PROTECTIVE AGENTS PRODRUG REDUCTION OF THE CUMULATIVE RENAL TOXICITY OF CISPLATIN AND FOR THE REDUCTION OF THE TOXIC EFFECTS OF RADIATION ON NORMAL ORAL TISSUES INTESTINAL-TYPE ALKALINE PHOSPHATASE (IAP) IS A MAJOR ISOENZYME INVOLVED IN THE HYDROLYSIS OF AMIFOSTINE (PMID12577238) |
|
ATC code
V03AF05 |
PK parameters Cmax 200 MICROMOLAR VD 7 LITER Cl 120 LITER / HOUR t1/2 0.13 HOUR
SolubilityFREELY SOLUBLE IN WATER
|
Target TARGET ALKALINE PHOSPHATASE |
DrugCentral Unknown |
Download SDF file |
2-(3-aminopropylamino)ethylsulfanylphosphonic acid Formula: C5H15N2O3PS Calculated chemical properties: MW 212.21 NB_atoms 12 XLogP -1.51 PSA 95.428 NB_HD 3 NB_HA 5 fsp3 1.00 Lipinski(0=no;1=yes) 1 |
FDA NDA 020221 ( label) INN (AMIFOSTINE) ETHYOL (LEGACY) APPROVAL= AP YEAR= 1995 NDA 077126 (pdf not found) INN (AMIFOSTINE) AMIFOSTINE (SUN PHARM) APPROVAL= AP YEAR= 2008 DISCONTINUED NDA 204363 (pdf not found) INN (AMIFOSTINE) AMIFOSTINE (EUGIA PHARMA SPECLTS) APPROVAL= AP YEAR= 2017 DISCONTINUED |
Other links: PubChem ChemicalProbes U.S. repository of Clinical Trials VigiAccess SIDER side effects ChemSynthesis Patent@SureChEMBL |